Skip to main content

Advertisement

SpringerLink
Log in

Characteristics of patients diagnosed with both melanoma and renal cell cancer

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Background

Patients with renal cell carcinoma (RCC) and malignant melanoma (MM) have an increased risk of additional malignancies. We identified characteristics of MM and RCC associated with a patient developing both cancers.

Methods

A total of 147,656 cases of RCC and 225,548 of MM submitted to the Surveillance, Epidemiology, and End Results database between 1973 and 2008 were analyzed. Standardized incidence ratios (SIR) with 95 % confidence intervals (CI) were calculated for MM after RCC and vice versa. Clinical and pathological characteristics were compared between patients with RCC or MM only and with both cancers using multivariable proportional hazards and competing risks regression models.

Results

Overall 1,241 patients developed both cancers. The crude incidence rates of RCC in patients with a prior MM diagnosis and vice versa were 5.2 and 9.4 per 10,000 person-years, respectively. There was an excess of MM in RCC patients (SIR 1.45, CI 1.34–1.57) and of RCC in MM patients (SIR 1.34, CI 1.25–1.43). Median years from RCC to MM diagnosis was 4.3 (2.0–7.8) and from MM to RCC 4.7(2.3–9.9). Patients with a history of MM had more papillary RCC (10.2 vs. 4.8 %, p = 0.01) and were more likely to be female (25.9 vs. 20.5 %, p < 0.001). On multivariable analyses, ocular MM was independently associated with subsequent RCC (HR 1.76 CI 1.24–2.49), as were increasing age, and male sex.

Conclusions

We confirmed a bidirectional association between RCC and MM. A history of MM was found to be associated with papillary RCC and advanced RCC. Ocular MM predicted an increased risk of RCC diagnosis. Further research is warranted into the mechanisms responsible for the association between RCC and MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK SEER Cancer Statistics Review, 1975–2008. Available from URL: http://seer.cancer.gov/csr/1975_2008/

  2. Navai N, Wood CG (2012) Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol 30:220–224

    Article  PubMed  Google Scholar 

  3. Park SL, Le Marchand L, Wilkens LR et al (2012) Risk factors for malignant melanoma in white and non-white/non–African American populations: the multiethnic cohort. Cancer Prev Res 5:423–434

    Article  Google Scholar 

  4. Stinauer MA, Kavanagh BD, Schefter TE et al (2011) Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 6:34

    Article  PubMed  Google Scholar 

  5. Cesana GC, DeRaffele G, Cohen S et al (2006) Characterization of CD4 + CD25 + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169–1177

    Article  PubMed  CAS  Google Scholar 

  6. Bracarda S, Eggermont AMM, Samuelsson J (2010) Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 46:284–297

    Article  PubMed  CAS  Google Scholar 

  7. Sabatino M, Kim-Schulze S, Panelli MC et al (2009) Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 27:2645–2652

    Article  PubMed  CAS  Google Scholar 

  8. Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH (2010) MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci 51:3333–3339

    Article  PubMed  Google Scholar 

  9. Lindor NM, Dechet CB, Greene MH et al (2001) Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 5:101–106

    Article  PubMed  CAS  Google Scholar 

  10. Lubensky IA, Schmidt L, Zhuang Z et al (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 155:517–526

    Article  PubMed  CAS  Google Scholar 

  11. Parrella P, Fazio VM, Gallo AP, Sidransky D, Merbs SL (2003) Fine mapping of chromosome 3 in uveal melanoma. Cancer Res 63:8507–8510

    PubMed  CAS  Google Scholar 

  12. Puri N, Ahmed S, Janamanchi V et al (2007) c-Met Is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246–2253

    Article  PubMed  CAS  Google Scholar 

  13. Bertolotto C, Lesueur F, Giuliano S et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480:94–98

    Article  PubMed  CAS  Google Scholar 

  14. Crocetti E, Guzzinati S, Paci E, et al (2008) The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res 18:230–234. doi:10.1097/CMR.0b013e3282fafd0a

    Google Scholar 

  15. Wu Y-H, Kim GH, Wagner JD, Hood AF, Chuang T-Y (2006) The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol 45:529–534

    Article  PubMed  Google Scholar 

  16. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M (2001) Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 145:981–985

    Article  PubMed  CAS  Google Scholar 

  17. Bradford PT, Freedman DM, Goldstein AM, Tucker MA (2010) Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146:265–272

    Article  PubMed  Google Scholar 

  18. Beisland C, Talleraas O, Bakke A, Norstein J (2006) Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 97:698–702

    Article  PubMed  Google Scholar 

  19. Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ (2012) Incidence and Prognostic Significance of Second Primary Cancers in Renal Cell Carcinoma. Am J Clin Oncol 36(2):132–142

    Google Scholar 

  20. Maubec E, Chaudru V, Mohamdi H et al (2010) Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer 116:5716–5724

    Article  PubMed  Google Scholar 

  21. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Research Data, Nov 2010 Sub (1973-2008) < Katrina/Rita Population Adjustment > —Linked To County Attributes—Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission

  22. Sahai H, Khurshid A (1993) Confidence intervals for the mean of a Poisson distribution: a review. Biometr J 35:857–867

    Article  Google Scholar 

  23. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154

    Article  Google Scholar 

  24. Sennino B, Ishiguro-Oonuma T, Wei Y et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270–287

    Article  PubMed  CAS  Google Scholar 

  25. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (eds) (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda, MD

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Duke Cancer Institute, Duke University Medical Center, 200 Trent Drive, DUMC Box 2804, Durham, NC, 27710, USA

    Michael R. Abern, Matvey Tsivian & Thomas J. Polascik

  2. Department of Urology, Rush University Medical Center, Chicago, IL, USA

    Christopher L. Coogan

  3. Department of General Surgery, Medicine, Rush University Medical Center, Chicago, IL, USA

    Howard L. Kaufman

  4. Department of Immunology and Microbiology, Rush University Medical Center, Chicago, IL, USA

    Howard L. Kaufman

Authors
  1. Michael R. Abern
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matvey Tsivian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher L. Coogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Howard L. Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas J. Polascik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. Abern.

Additional information

Michael R. Abern and Matvey Tsivian have contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abern, M.R., Tsivian, M., Coogan, C.L. et al. Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control 24, 1925–1933 (2013). https://doi.org/10.1007/s10552-013-0267-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-013-0267-0

Keywords

Search

Navigation